Edition:
United Kingdom

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,650JPY
23 May 2018
Change (% chg)

-- (--)
Prev Close
¥1,650
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
7,863,013
52-wk High
¥1,698
52-wk Low
¥1,332

Chart for

About

Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive... (more)

Overall

Beta: 0.60
Market Cap(Mil.): ¥3,012,207.00
Shares Outstanding(Mil.): 2,068.82
Dividend: 18.00
Yield (%): 2.34

Financials

  4503.T Industry Sector
P/E (TTM): 15.71 30.95 32.75
EPS (TTM): 92.68 -- --
ROI: 13.91 14.84 14.38
ROE: 15.50 16.34 16.07

BRIEF- Astellas Pharma signs exclusive licensing agreement with Aquinox Pharmaceuticals

* Says it signed an exclusive license agreement with Aquinox Pharmaceuticals, Inc for Japan and certain other countries in the Asia-Pacific region for Astellas to develop and commercialize rosiptor, Aquinox’s lead drug candidate, a first-in-class, once-daily oral treatment currently in Phase 3 clinical development for interstitial cystitis/bladder pain syndrome (IC/BPS) in North America and Europe

10 May 2018

BRIEF-Aquinox And Astellas Announce Exclusive Licensing Agreement For Rosiptor In Asia-Pacific Region Including Japan

* AQUINOX AND ASTELLAS ANNOUNCE EXCLUSIVE LICENSING AGREEMENT FOR ROSIPTOR IN ASIA-PACIFIC REGION INCLUDING JAPAN

10 May 2018

BRIEF-FDA Approves Supplemental New Drug Application For Myrbetriq For Treatment Of Overactive Bladder Symptoms

* FDA APPROVES SUPPLEMENTAL NEW DRUG APPLICATION FOR MYRBETRIQ® (MIRABEGRON) FOR USE IN COMBINATION WITH SOLIFENACIN SUCCINATE FOR THE TREATMENT OF OVERACTIVE BLADDER SYMPTOMS

08 May 2018

BRIEF-Astellas Pharma to retire treasury shares

* Says it will retire 89 million shares(4.3 percent stake) of its common stock on May 31

26 Apr 2018

BRIEF-Astellas Says To Cancel Treasury Stock Equivalent To 4.3 Percent Of Shares Outstanding

* ASTELLAS SAYS TO CANCEL TREASURY STOCK EQUIVALENT TO 4.3 PERCENT OF SHARES OUTSTANDING Further company coverage: (Reporting By Chris Gallagher)

26 Apr 2018

BRIEF-Astellas Pharma Submits NDA For Approval Of Gilteritinib

* ASTELLAS SUBMITS NEW DRUG APPLICATIONS FOR APPROVAL OF GILTERITINIB FOR THE TREATMENT OF FLT3MUT+ RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

24 Apr 2018

BRIEF-Proteostasis Therapeutics - Co & Astellas Pharma Entered Into Amendment No. 6 To Collaboration & License Agreement

* PROTEOSTASIS THERAPEUTICS - ON APRIL 20, CO & ASTELLAS PHARMA ENTERED INTO AMENDMENT NO. 6 TO COLLABORATION & LICENSE AGREEMENT DATED NOVEMBER 4, 2014

23 Apr 2018

BRIEF-Astellas Announces Sale Of Certain Agensys Research Facilities To Kite, A Gilead Co

* ASTELLAS ANNOUNCES SALE OF CERTAIN AGENSYS RESEARCH FACILITIES TO KITE, A GILEAD COMPANY

18 Apr 2018

BRIEF-Cardurion Pharmaceuticals Licenses Clinical Stage Heart Failure Candidate From Astellas

* CARDURION PHARMACEUTICALS LICENSES CLINICAL STAGE HEART FAILURE CANDIDATE FROM ASTELLAS

16 Apr 2018

BRIEF- Astellas Pharma completes share repurchase

* Says it completes repurchase of 39.6 million shares of its common stock, for 60 billion yen in total, during period from Feb. 1 to March 23

26 Mar 2018

Earnings vs. Estimates